Press release
Health Care
June 2, 2015

New study confirms that the anthocyanins in Healthberry™ 865 have a positive effect on individuals with type 2 diabetes

A new study has confirmed the antioxidant properties of anthocyanins and their positive effects on the human cardiovascular system. The study was performed using Medox®, a nutritional supplement made by Biolink AS. Evonik has recently begun marketing the powdered extract of Scandinavian blueberries and blackcurrants throughout the world as Healthberry™ 865.

A collaborative effort both with Sun Yat-sen University in Guangzhou, China, and with the Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, this randomized, placebo-controlled, double-blind study investigated the effects of daily doses of 320 milligrams of Healthberry™ 865 among 58 subjects with type 2 diabetes. The study showed that the supplement significantly reduced the concentration of LDL cholesterol and triglycerides in the blood, and elevated concentrations of HDL cholesterol. Healthberry™ 865 was also found to have a significant positive effect on blood glucose levels and on patients’ insulin resistance index.

The results confirm again what over 20 other studies worldwide have already shown: diet supplementation with Healthberry™ 865 has a proven positive effect on human metabolism in general and on that of individuals with type 2 diabetes in particular.

The publication appeared in the distinguished Journal of Nutrition (Li et al., Journal of Nutrition doi: 10.3945/jn.114.205674, published ahead of printing, February 2015).

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2014 more than 33,000 employees generated sales of around €12.9 billion and an operating profit (adjusted EBITDA) of about €1.9 billion.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.